1,2-Dihydronaphthalene-2,3-dicarboxylic | 52144-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,2-Dihydronaphthalene-2,3-dicarboxylic
• 英文别名: 1,2-dihydronaphthalene-2,3-dicarboxylic acid
• CAS: 52144-41-9
• 化学式: C₁₂H₁₀O₄
• 分子量: 218.209
• InChiKey: CNDMOEUUJLPXSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 1,2-Dihydronaphthalene-2,3-dicarboxylic 以70%的产率得到rac-2,3-dicarbomethoxy-3,4-dihydronaphthalene
  参考文献：
  名称：

  Thermal generation of alpha-hydroxy-orthoquinodimethane and reaction with the fumarate, maleate and acrylate of S-methyl lactate

  摘要：

  DOI：

  10.1016/s0040-4039(00)99221-9
• 作为产物：
  描述：

  1-羟基-苯并环丁烯 、 (S)-Methyl lactyl fumarate 生成 1,2-Dihydronaphthalene-2,3-dicarboxylic
  参考文献：
  名称：

  Thermal generation of alpha-hydroxy-orthoquinodimethane and reaction with the fumarate, maleate and acrylate of S-methyl lactate

  摘要：

  DOI：

  10.1016/s0040-4039(00)99221-9

文献信息

• CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET
  申请人：Centre National de la Recherche Scientifique

  公开号：EP3436601A1

  公开（公告）日：2019-02-06
• [EN] CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET<br/>[FR] NIVEAU D'EXPRESSION DE LA CYTIDINE DÉSAMINASE DANS UN CANCER EN TANT QUE NOUVELLE CIBLE THÉRAPEUTIQUE
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2017167989A1

  公开（公告）日：2017-10-05

  The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.